ASCO 2019 – Macrogenics builds a case for margetuximab

cafead

Administrator
Staff member
  • cafead   Jun 05, 2019 at 09:52: AM
via Demonstrating an overall survival benefit remains crucial for Macrogenics’ anti-Her2 antibody margetuximab, for regulatory approval and any partnering deals alike.

article source
 

<